Sharing is caring : a call for a new era of rare disease research and development
© 2022. The Author(s)..
Scientific advances in the understanding of the genetics and mechanisms of many rare diseases with previously unknown etiologies are inspiring optimism in the patient, clinical, and research communities and there is hope that disease-specific treatments are on the way. However, the rare disease community has reached a critical point in which its increasingly fragmented structure and operating models are threatening its ability to harness the full potential of advancing genomic and computational technologies. Changes are therefore needed to overcome these issues plaguing many rare diseases while also supporting economically viable therapy development. In "Data silos are undermining drug development and failing rare disease patients (Orphanet Journal of Rare Disease, Apr 2021)," we outlined many of the broad issues underpinning the increasingly fragmented and siloed nature of the rare disease space, as well as how the issues encountered by this community are representative of biomedical research more generally. Here, we propose several initiatives for key stakeholders - including regulators, private and public foundations, and research institutions - to reorient the rare disease ecosystem and its incentives in a way that we believe would cultivate and accelerate innovation. Specifically, we propose supporting non-proprietary patient registries, greater data standardization, global regulatory harmonization, and new business models that encourage data sharing and research collaboration as the default mode. Leadership needs to be integrated across sectors to drive meaningful change between patients, industry, sponsors, and academic medical centers. To transform the research and development landscape and unlock its vast healthcare, economic, and scientific potential for rare disease patients, a new model is ultimately the goal for all.
Errataetall: |
ErratumIn: Orphanet J Rare Dis. 2023 Jan 23;18(1):15. - PMID 36691034 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
Orphanet journal of rare diseases - 17(2022), 1 vom: 27. Okt., Seite 389 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Denton, Nathan [VerfasserIn] |
---|
Links: |
---|
Themen: |
Clinical trials |
---|
Anmerkungen: |
Date Completed 31.10.2022 Date Revised 23.01.2023 published: Electronic ErratumIn: Orphanet J Rare Dis. 2023 Jan 23;18(1):15. - PMID 36691034 Citation Status MEDLINE |
---|
doi: |
10.1186/s13023-022-02529-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM348175329 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM348175329 | ||
003 | DE-627 | ||
005 | 20231226035549.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13023-022-02529-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1160.xml |
035 | |a (DE-627)NLM348175329 | ||
035 | |a (NLM)36303170 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Denton, Nathan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Sharing is caring |b a call for a new era of rare disease research and development |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 31.10.2022 | ||
500 | |a Date Revised 23.01.2023 | ||
500 | |a published: Electronic | ||
500 | |a ErratumIn: Orphanet J Rare Dis. 2023 Jan 23;18(1):15. - PMID 36691034 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s). | ||
520 | |a Scientific advances in the understanding of the genetics and mechanisms of many rare diseases with previously unknown etiologies are inspiring optimism in the patient, clinical, and research communities and there is hope that disease-specific treatments are on the way. However, the rare disease community has reached a critical point in which its increasingly fragmented structure and operating models are threatening its ability to harness the full potential of advancing genomic and computational technologies. Changes are therefore needed to overcome these issues plaguing many rare diseases while also supporting economically viable therapy development. In "Data silos are undermining drug development and failing rare disease patients (Orphanet Journal of Rare Disease, Apr 2021)," we outlined many of the broad issues underpinning the increasingly fragmented and siloed nature of the rare disease space, as well as how the issues encountered by this community are representative of biomedical research more generally. Here, we propose several initiatives for key stakeholders - including regulators, private and public foundations, and research institutions - to reorient the rare disease ecosystem and its incentives in a way that we believe would cultivate and accelerate innovation. Specifically, we propose supporting non-proprietary patient registries, greater data standardization, global regulatory harmonization, and new business models that encourage data sharing and research collaboration as the default mode. Leadership needs to be integrated across sectors to drive meaningful change between patients, industry, sponsors, and academic medical centers. To transform the research and development landscape and unlock its vast healthcare, economic, and scientific potential for rare disease patients, a new model is ultimately the goal for all | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Clinical trials | |
650 | 4 | |a Data management | |
650 | 4 | |a Drug development | |
650 | 4 | |a Knowledge bases | |
650 | 4 | |a Rare diseases | |
650 | 4 | |a Registries | |
650 | 4 | |a Research design | |
700 | 1 | |a Mulberg, Andrew E |e verfasserin |4 aut | |
700 | 1 | |a Molloy, Monique |e verfasserin |4 aut | |
700 | 1 | |a Charleston, Samantha |e verfasserin |4 aut | |
700 | 1 | |a Fajgenbaum, David C |e verfasserin |4 aut | |
700 | 1 | |a Marsh, Eric D |e verfasserin |4 aut | |
700 | 1 | |a Howard, Paul |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Orphanet journal of rare diseases |d 2006 |g 17(2022), 1 vom: 27. Okt., Seite 389 |w (DE-627)NLM163016410 |x 1750-1172 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2022 |g number:1 |g day:27 |g month:10 |g pages:389 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13023-022-02529-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 17 |j 2022 |e 1 |b 27 |c 10 |h 389 |